difference between tirzepatide and retatrutide vs for weight loss Retatrutide vs tirzepatide dosage chart:

This triple-action mechanism distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)

Many patients benefit from prioritizing high-protein foods throughout the day to help support muscle retention and satiety during weight loss

Retatrutide is an investigational triple-agonist (GLP-1, GIP, and glucagon) with a half-life of roughly 6 days (Coskun et al., Cell Metabolism, 2022)

The 0.25mg dose does not produce meaningful weight loss or blood sugar reduction on its own

Indirect effects An indirect pathway for GLP-1RAs to mediate risk for PDAC is via acute or chronic pancreatitis, which are risk factors for PDAC 24,25

Burping in GERD patients often brings stomach acid into the esophagus, causing heartburn and potentially damaging esophageal tissue